Introducing misoprostol for treatment of incomplete abortion: A feasibility and acceptability study in secondary-level health facilities in Myanmar.


Journal

Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives
ISSN: 1877-5764
Titre abrégé: Sex Reprod Healthc
Pays: Netherlands
ID NLM: 101530546

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 20 07 2022
revised: 16 01 2023
accepted: 13 02 2023
medline: 7 6 2023
pubmed: 27 2 2023
entrez: 26 2 2023
Statut: ppublish

Résumé

To assess the feasibility and acceptability of misoprostol as a treatment option for incomplete abortion in secondary hospitals in Yangon and Mandalay, Myanmar. An explanatory sequential mixed methods study was conducted. Women seeking treatment for an incomplete abortion with a uterine size <12 weeks were eligible to participate in the prospective cohort including sublingual administration of 400 μg misoprostol, clinical assessment 7-10 days after administration, and patient interview. Treatment efficacy was assessed, defined as proportion of participants with complete uterine evacuation with misoprostol alone. After the cohort, provider interviews were conducted to understand how their experiences with misoprostol may have influenced cohort findings. Study sites included seventeen secondary health facilities in four townships in Yangon and Mandalay, Myanmar. A total of 110 women were enrolled from July 2018 to January 2019; 96 completed follow-up. In 75 % of cases, incomplete abortion was successfully treated with misoprostol. Treatment efficacy varied significantly by region (Yangon 85 %, Mandalay 67 %; p = 0.048), driven by providers' variable comfort with misoprostol and proclivity to intervene with additional treatment. With experience, all were willing to incorporate the protocol into practice by study end. Patient acceptability and satisfaction were high. Misoprostol is an acceptable and feasible treatment option for women seeking postabortion care at secondary facilities in Myanmar. Extensive health provider training and support systems and continued implementation experience are crucial to effectively translate clinical PAC guidelines into practice in Myanmar.

Identifiants

pubmed: 36842188
pii: S1877-5756(23)00015-0
doi: 10.1016/j.srhc.2023.100825
pii:
doi:

Substances chimiques

Misoprostol 0E43V0BB57
Abortifacient Agents, Nonsteroidal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100825

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Meighan Mary (M)

Gynuity Health Projects, New York, NY, USA. Electronic address: mtarnagada@gynuity.org.

Khaing Nwe Tin (KN)

Ministry of Health and Sports, Nay Pyi Taw, Myanmar.

Thae Maung Maung (TM)

Department of Medical Research, Yangon, Myanmar.

Hein Nyi Maung (HN)

Mandalay, Myanmar.

Saw Kler Ku (SK)

Obstetrics and Gynecology Department, University of Medicine 2, Yangon, Myanmar.

Beverly Winikoff (B)

Gynuity Health Projects, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH